



## EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

October 31, 2023

### - KOLs to provide insight and discussion of EYP-1901 in wet AMD and topline data considerations for the DAVIO 2 clinical trial

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET.

This event will focus on the potential of EYP-1901 in wet age-related macular degeneration (wet AMD), including KOL perspectives on the current wet AMD treatment landscape, vorolanib's unique mechanism of action and outcome considerations for the upcoming topline data read-out for the DAVIO 2 trial in December. The event will be moderated by EyePoint's President and Chief Executive Officer, Jay S. Duker, M.D., and will feature presentations from the following retinal experts:

- **David S. Boyer, M.D.**, Senior Partner at Retina-Vitreous Associates Medical Group, Adjunct Clinical Professor of Ophthalmology at University of Southern California, Keck School of Medicine
- **David R. Lally, M.D.**, Retinal Surgeon at Baystate Medical Center, Assistant Professor of Ophthalmology at the University of Massachusetts Medical School-Baystate, Director of Retina Research Institute at New England Retinal Consultants

To access the live conference call, please register using the audio conference link: <https://register.vevent.com/register/BI7011e8a8a96a408b91e23c1c3f598ede>. A live audio webcast of the event can be accessed via the Investors section of the Company website at [www.eyepointpharma.com](http://www.eyepointpharma.com). A webcast replay will also be available on the corporate website at the conclusion of the call.

#### About EYP-1901

EYP-1901 is being developed as an investigational sustained delivery treatment for retinal disease combining a bioerodible formulation of EyePoint's proprietary Durasert<sup>®</sup> delivery technology (Durasert E<sup>™</sup>) with vorolanib, a tyrosine kinase inhibitor. Results from the Phase 1 DAVIO clinical trial of EYP-1901 in wet AMD showed a positive safety profile with stable visual acuity and OCT. Further, the data demonstrated an impressive treatment burden reduction of 75% at six months and 73% at the 12-month visit following a single dose of EYP-1901. Phase 2 trials are fully enrolled in wet AMD and non-proliferative diabetic retinopathy, and a diabetic macular edema trial is planned for initiation in Q1 2024. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases.

#### About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E<sup>™</sup> technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert<sup>®</sup> drug delivery platform has been safely administered to over 80,000 patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit [www.eyepointpharma.com](http://www.eyepointpharma.com).

#### Investors:

Christina Tartaglia  
Stern IR  
Direct: 212-698-8700  
[christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)

#### Media Contact:

Amy Phillips  
Green Room Communications  
Direct: 412-327-9499  
[aphillips@greenroompr.com](mailto:aphillips@greenroompr.com)



Source: EyePoint Pharmaceuticals, Inc.